Top Page
BioInvent International AB
(BINV)
BioInvent International AB (BINV) vs. iShares MSCI Sweden ETF (EWD)
BioInvent International AB Business Overview & Revenue Model
BioInvent International AB Earnings Call Summary
BioInvent International AB Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 244.85M | 44.69M | 71.46M | 326.13M | 19.38M | 147.37M |
| Gross Profit | 241.53M | 44.69M | 71.46M | 326.13M | 19.38M | 147.37M |
| EBITDA | -314.75M | -409.38M | -312.71M | -27.13M | -263.32M | -63.99M |
| Net Income | -323.94M | -429.38M | -330.30M | -34.09M | -278.96M | -76.67M |
Balance Sheet | ||||||
| Total Assets | 785.82M | 989.24M | 1.40B | 1.71B | 1.45B | 802.64M |
| Cash, Cash Equivalents and Short-Term Investments | 690.46M | 867.16M | 1.07B | 1.02B | 1.08B | 729.27M |
| Total Debt | 10.69M | 17.41M | 23.24M | 26.96M | 28.37M | 11.60M |
| Total Liabilities | 102.80M | 103.42M | 90.45M | 106.09M | 80.32M | 59.14M |
| Stockholders Equity | 683.02M | 885.82M | 1.31B | 1.61B | 1.37B | 743.50M |
Cash Flow | ||||||
| Free Cash Flow | -262.35M | -390.50M | -355.00M | -53.60M | -259.10M | -69.32M |
| Operating Cash Flow | -255.51M | -380.47M | -341.69M | -41.23M | -245.84M | -62.62M |
| Investing Cash Flow | 39.10M | 564.35M | 59.68M | -628.85M | -467.54M | -6.70M |
| Financing Cash Flow | -8.96M | -8.46M | 23.14M | 273.49M | 894.87M | 644.62M |
BioInvent International AB Technical Analysis
BioInvent International AB Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | kr2.93B | 4.62 | 167.77% | ― | 2687.51% | ― | |
67 Neutral | kr1.24B | 9.82 | 81.19% | ― | ― | ― | |
58 Neutral | kr3.51B | -6.77 | -71.87% | ― | -91.85% | -6.65% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | kr1.99B | -6.16 | -36.52% | ― | 533.73% | 20.92% | |
44 Neutral | kr1.29B | -5.24 | -35.03% | ― | ― | 25.14% | |
41 Neutral | kr3.26B | -3.60 | ― | ― | -5.69% | 21.58% |
BioInvent International AB Corporate Events
BioInvent International has reported encouraging interim Phase 2a data for its first‑in‑class anti‑TNFR2 antibody BI‑1808 in combination with Merck’s anti‑PD‑1 therapy KEYTRUDA (pembrolizumab) in patients with recurrent ovarian cancer who have progressed after platinum‑based treatment. Among 17 evaluable patients, the combination achieved a 24% overall response rate and 65% disease control rate, a marked improvement over the 8% response rate previously seen with pembrolizumab monotherapy in this setting, with responses including durable stable disease beyond eight months and a generally favorable safety and tolerability profile. Exploratory analyses suggest strong activity in high‑grade serous and clear cell ovarian cancer subtypes, prompting BioInvent to expand the ovarian cancer cohort by enrolling an additional 20 patients, with results expected in the second half of 2026, potentially strengthening the company’s position in immuno‑oncology and offering a new treatment avenue for a patient population with few effective options.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK28.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
BioInvent International AB will seek to deepen engagement with global investors and industry partners in January 2026 through participation in several high-profile investor and healthcare conferences in San Francisco and Stockholm. The company’s management will hold one-on-one meetings at the J.P. Morgan 2026 Healthcare Conference and the LifeSci Partners Corporate Access Event, join a Swedish-focused panel at the J.P. Morgan networking breakfast, and present with a Q&A session at the Redeye Fight Cancer event, moves that underscore its efforts to raise visibility around its cancer immunotherapy pipeline and to support potential partnering and financing opportunities.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK28.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
BioInvent International AB announced promising early data from its Phase 2a trial of BI-1206 in combination with rituximab and Calquence for the treatment of relapsed/refractory non-Hodgkin’s lymphoma (NHL). The trial showed an 80% overall response rate, with 47% of patients achieving complete responses and a favorable safety profile, suggesting the potential of this combination to overcome resistance to rituximab and provide a new therapeutic option for patients with limited alternatives.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK28.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
BioInvent International AB has presented promising early Phase 2a data for its BI-1808 monotherapy in treating cutaneous T-cell lymphoma (CTCL) at the ASH 2025 meeting. The trial showed a 46% objective response rate and a 92% disease control rate among evaluable patients, with evidence of immune activation. The company is also exploring BI-1808 in combination with pembrolizumab for solid tumors, positioning itself for significant market opportunities with Fast Track and Orphan Drug designations.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK28.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
BioInvent International AB has published preclinical and early Phase 1 data for BI-1607, a novel FcγRIIB-blocking monoclonal antibody, in the journal Clinical Cancer Research. The study shows promising disease control in HER2-positive advanced solid tumors, with 78% of patients experiencing stable disease. Although the BI-1607 program is currently paused, the data supports the potential of Fcγ monoclonal antibodies in enhancing cancer treatment efficacy, particularly in combination with other therapeutic antibodies like trastuzumab.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK34.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
BioInvent International AB announced that the European Medicines Agency’s Committee for Orphan Medicinal Products has given a positive opinion for Orphan Drug Designation to its investigational product BI-1808 for treating Cutaneous T-cell Lymphoma (CTCL). This designation is expected to promote the development of drugs for rare diseases, offering incentives like protocol assistance and market exclusivity. BI-1808 has shown promising clinical activity with a 100% disease control rate in a Phase 2a trial, and it is well-tolerated with mild to moderate adverse events. The European Commission is anticipated to grant the designation within 30 days, which underscores BioInvent’s commitment to advancing novel immunotherapies for underserved hematologic malignancies.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK34.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
BioInvent International AB announced promising Phase 1 clinical data for its TNFR2 agonist antibody, BI-1910, presented at the SITC 2025 Annual Meeting. The study showed that BI-1910 can activate immune responses and induce disease control in patients with advanced solid tumors, with 12 out of 26 patients achieving stable disease. Despite these positive results, BioInvent has paused the development of BI-1910 to focus on its more advanced program, BI-1808, which is progressing in Phase 2 clinical development.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK34.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
BioInvent International AB announced that it will present early Phase 2a data from its ongoing trial of a triple combination therapy involving BI-1206, rituximab, and Calquence for treating non-Hodgkin’s lymphoma (NHL) at the ASH 2025 meeting. The data indicates that the combination is safe and well-tolerated, with promising efficacy signals, and the company is optimistic about advancing to the next phase to potentially improve patient outcomes and the standard of care.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK34.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
BioInvent International AB announced the presentation of updated Phase 2a data for its BI-1808 monotherapy at the 2025 ASH Annual Meeting. The data highlights the treatment’s promising efficacy and safety profile in cutaneous T-cell lymphoma (CTCL), with no severe adverse events reported and a high disease control rate. BI-1808 has received Fast Track and Orphan Drug Designations from the FDA, underscoring its potential impact on patients with unmet medical needs.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK34.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
BioInvent International AB announced a strategic shift to prioritize its advanced clinical programs, BI-1206 and BI-1808, aiming to accelerate their development and enhance value creation. The company is set to achieve several key milestones in the second half of 2025, including additional data releases for its treatments targeting cutaneous T-cell lymphoma and non-Hodgkin’s lymphoma, as well as a Phase 2a study for solid tumors. This strategic focus is expected to strengthen BioInvent’s position in the immuno-oncology sector and potentially impact stakeholders positively by advancing promising cancer therapies.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK29.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
BioInvent International AB has announced an upcoming presentation of its interim report for January to September 2025, scheduled for October 29, 2025. The presentation will be led by CEO Martin Welschof and CFO Stefan Ericsson, providing insights into the company’s financial performance and ongoing clinical programs. Stakeholders can participate via webcast or teleconference, highlighting BioInvent’s commitment to transparency and engagement with investors and analysts.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK29.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
BioInvent International AB and Transgene have announced positive clinical results for their oncolytic virus BT-001, which shows promising antitumoral activity in combination with pembrolizumab in patients with advanced refractory tumors. The data presented at the ESMO 2025 Annual Meeting indicate that BT-001 is well tolerated and effective in shrinking tumors, supporting further development across a range of solid tumors. This development could enhance treatment options for cancer patients, particularly those with limited alternatives, by transforming cold tumors into immunologically active ones.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK29.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
BioInvent International AB and Transgene have announced the presentation of translational data and updated clinical results for their oncolytic virus BT-001 at the ESMO 2025 Annual Meeting. The Phase 1 study results indicate that BT-001, in combination with pembrolizumab, shows promise as a treatment for advanced refractory tumors, demonstrating tumor shrinkage in both injected and non-injected lesions. This development could enhance the response to immune checkpoint inhibitors in refractory patients, potentially impacting the company’s position in the cancer immunotherapy market.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK29.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.